Biotech podcast reviews FDA hearings, executive shake-ups and a fugitive exec
The latest “The Readout LOUD” episode covers Capricor Therapeutics’ FDA advisory meeting on a Duchenne drug, Replimmune’s melanoma immunotherapy discussion, and recent leadership changes at GSK and Sarepta.
In this week’s “The Readout LOUD” biotech briefing, Allison, Elaine and Adam analyze Capricor Therapeutics’ appearance before an FDA advisory committee, where the company sought clearance for a Duchenne muscular dystrophy therapy amid questions about its presented data. The trio also review Replimmune’s advisory meeting concerning its experimental melanoma immunotherapy. Additional topics include recent cost-cutting measures announced by GSK, the selection of a new chief executive for Sarepta Therapeutics, and a revealing account of a fugitive who once served as a biotech executive.
Listeners are invited to subscribe on major podcast platforms. The episode ties together regulatory scrutiny, drug development pipelines, and notable corporate personnel shifts within the life-sciences sector.
Why it matters
It highlights regulatory hurdles and leadership moves that could shape upcoming biotech treatments and market dynamics.
In this story